Wegovy 25 mg Tablets: Semaglutide Medical Information (Australia)
Wegovy 25 mg tablets contain semaglutide, an oral glucagon-like peptide-1 (GLP-1) receptor agonist used as part of medical weight management in eligible adults. The 25 mg tablet is the maintenance strength in the published dose-escalation schedule for oral Wegovy.
This page explains the 25 mg tablet, its role in treatment, how oral semaglutide works, administration considerations, potential side effects and important safety information for Australian readers.
Important: Wegovy is a prescription medicine. The appropriate dose and treatment plan must be determined by a qualified healthcare professional. This article is general educational information and should not replace the current Australian Product Information (PI), Consumer Medicine Information (CMI), or advice from a doctor or pharmacist.
Wegovy 25 mg Tablets: Product Overview
| Product detail | Information |
|---|---|
| Brand name | Wegovy |
| Active ingredient | Semaglutide |
| Tablet strength | 25 mg |
| Dosage form | Oral tablet |
| Medicine class | GLP-1 receptor agonist |
| Route of administration | Oral |
| Dose stage | Maintenance strength in the published oral dose schedule |
| Australian ARTG ID | 522759 |
| Australian ARTG date | 3 November 2026 |
| Australian sponsor | Novo Nordisk Pharmaceuticals Pty Ltd |
| Prescription status | Prescription medicine |
The Australian Register of Therapeutic Goods (ARTG) lists Wegovy semaglutide 25 mg tablet blister packs under ARTG number 522759. Registration should not be confused with immediate pharmacy availability. Check current Australian regulatory and supply information before making availability claims.
What Is Wegovy 25 mg tablets ?
Wegovy 25 mg tablets is the highest tablet strength in the published oral Wegovy dose-escalation schedule. It contains semaglutide, a medicine that acts on GLP-1 receptors involved in appetite regulation, food intake and blood glucose control.
Semaglutide can help eligible patients manage body weight when used alongside an appropriate reduced-energy diet, increased physical activity and ongoing clinical support.
The 25 mg tablet is intended as a maintenance dose after the earlier dose-escalation stages. It is not intended to be used as an initial dose unless a prescriber has provided specific instructions consistent with the approved product information.
How Does Oral Semaglutide Work?
Semaglutide acts on GLP-1 receptors, which are involved in several processes related to appetite and metabolism.
Its effects may include:
- Appetite regulation: Influences appetite-related signalling in the brain.
- Increased fullness: May help people feel satisfied after eating.
- Reduced food intake: May reduce hunger and the amount of food consumed.
- Gastric emptying: Can slow the movement of food from the stomach, particularly during treatment.
- Blood glucose regulation: Supports glucose-dependent insulin secretion and reduces glucagon secretion.
These effects can contribute to weight management. Individual responses vary, and treatment outcomes depend on several factors, including medical history, adherence, lifestyle and tolerability.
Why Is 25 mg the Maintenance Strength?
Oral Wegovy uses a gradual dose-escalation schedule. The treatment begins with a lower tablet strength before progressing through higher strengths.
The published schedule is:
| Treatment stage | Tablet strength | General schedule |
|---|---|---|
| Starting stage | 1.5 mg | First month |
| Dose escalation | 4 mg | Second month |
| Dose escalation | 9 mg | Third month |
| Maintenance stage | 25 mg | After escalation |
The gradual approach is intended to help the body adjust to treatment and improve gastrointestinal tolerability.
The 25 mg tablet should only be used when the prescriber has determined that the patient is ready to progress to the maintenance stage. Patients should not increase their dose independently or take additional tablets to compensate for a missed dose.
How to Take Wegovy 25 mg Tablets
Oral semaglutide has specific administration requirements because the amount absorbed can be affected by food, beverages and other medicines.
The published administration instructions for oral Wegovy include:
- Take the tablet in the morning after an overnight fast of at least eight hours.
- Swallow the tablet whole with a small amount of plain water, up to 120 mL.
- Do not split, crush or chew the tablet.
- Wait at least 30 minutes before eating, drinking or taking other oral medicines.
Follow the instructions supplied with the Australian product and confirm any questions with a pharmacist. Do not change the timing or method of administration without professional advice.
What Happens If a Dose Is Missed?
If a Wegovy 25 mg tablets dose is missed, patients should follow the current Australian Consumer Medicine Information and their prescriber’s instructions.
Do not take an extra tablet or double the next dose to make up for a missed dose. If several doses have been missed, contact the prescribing healthcare professional before restarting or changing treatment.
Possible Side Effects of Wegovy 25 mg tablets
Like other medicines containing semaglutide, oral Wegovy may cause side effects. Gastrointestinal symptoms are among the commonly reported effects of semaglutide treatment.
Potential side effects include:
- Nausea
- Vomiting
- Diarrhoea
- Constipation
- Abdominal discomfort or pain
- Bloating
- Indigestion
- Reduced appetite
Symptoms may be more noticeable during dose escalation or after an increase in dose. Not everyone experiences side effects, and their severity can vary.
Serious Side Effects and When to Seek Medical Advice
Some symptoms may indicate a more serious problem and require prompt medical assessment.
Seek urgent medical advice for severe or persistent abdominal pain, particularly if it spreads to the back or occurs with vomiting. This may require assessment for pancreatitis.
Other symptoms requiring medical attention can include:
- Persistent vomiting or diarrhoea, especially if dehydration develops.
- Symptoms suggestive of gallbladder problems, such as significant upper abdominal pain.
- Signs of a serious allergic reaction, including swelling of the face or throat, difficulty breathing or a widespread severe reaction.
- Significant changes in vision or other unexpected symptoms.
For severe allergic symptoms or difficulty breathing, seek emergency medical assistance.
Who Should Discuss Wegovy Treatment Carefully With a Doctor?
Wegovy may not be appropriate for everyone. Before treatment, patients should discuss their medical history, current medicines and relevant health conditions with their prescriber.
Particular care may be required for people with:
- A history of pancreatitis.
- Gallbladder disease.
- Significant gastrointestinal conditions.
- Kidney problems, particularly where vomiting or diarrhoea could cause dehydration.
- Diabetes treated with insulin or medicines that can cause hypoglycaemia.
- A history of diabetic retinopathy.
- Pregnancy, plans to become pregnant or breastfeeding.
Semaglutide should not be used for weight reduction during pregnancy. Anyone who is pregnant, planning pregnancy or breastfeeding should discuss treatment with their healthcare professional.
The current Australian PI should be consulted for the complete list of contraindications, warnings and precautions.
Wegovy 25 mg tablets and Medicine Interactions
Semaglutide may affect the rate at which the stomach empties. This can influence the absorption of some medicines taken by mouth.
Patients should tell their doctor and pharmacist about all medicines they use, including:
- Prescription medicines.
- Non-prescription medicines.
- Vitamins and supplements.
- Other medicines used for diabetes or weight management.
Particular attention may be needed when semaglutide is used with insulin or sulfonylureas because the risk of low blood glucose may increase.
Do not combine Wegovy with another semaglutide-containing medicine or another GLP-1 receptor agonist unless a qualified prescriber has specifically assessed and directed the treatment.
Wegovy 25 mg Tablets vs Wegovy Injection
Both oral and injectable Wegovy contain semaglutide, but they have different formulations and administration schedules.
| Feature | Wegovy 25 mg tablet | Wegovy injection |
|---|---|---|
| Active ingredient | Semaglutide | Semaglutide |
| Administration | Oral | Subcutaneous injection |
| Schedule | Once daily | Once weekly |
| Maintenance strength | 25 mg tablet | Common adult maintenance dose has been 2.4 mg weekly, subject to current PI |
| Administration considerations | Requires fasting and a waiting period before food, drinks and other oral medicines | Does not require the same fasting routine |
| Dose conversion | Not a direct milligram-for-milligram conversion | Requires clinician-directed treatment planning |
Although the oral 25 mg and injectable 2.4 mg regimens may provide comparable semaglutide exposure in relevant populations, the doses are not interchangeable by simple milligram calculation. Switching between formulations must be guided by a healthcare professional.
Wegovy 25 mg vs Rybelsus
Wegovy and Rybelsus both contain semaglutide, but they are different prescription products with different approved uses, strengths and dosing instructions.
Rybelsus is an oral semaglutide product registered in Australia for type 2 diabetes. Wegovy tablets have a separate product registration and include strengths intended for the oral weight-management dose schedule.
Patients should not substitute Rybelsus for Wegovy or combine the products without medical direction.
Is Wegovy 25 mg tablets Approved in Australia?
The Therapeutic Goods Administration (TGA) lists Wegovy semaglutide 25 mg tablet blister packs on the Australian Register of Therapeutic Goods.
The public ARTG record identifies:
- Product: Wegovy semaglutide 25 mg tablet blister pack
- ARTG number: 522759
- ARTG date: 3 November 2026
- Sponsor: Novo Nordisk Pharmaceuticals Pty Ltd
- Active ingredient: Semaglutide
TGA registration and commercial supply are separate matters. Registration does not necessarily mean that the product is already stocked by pharmacies or available for immediate dispensing. Patients should ask their pharmacist or healthcare professional about current Australian supply arrangements.
The product’s approved indications, eligibility criteria, warnings and administration requirements should be checked against the current Australian PI.
Frequently Asked Questions About Wegovy 25 mg tablets
What is Wegovy 25 mg tablets used for?
Wegovy 25 mg tablets is the maintenance tablet strength in the published oral semaglutide dose-escalation schedule. It is used as part of a clinician-supervised treatment plan for eligible adults, according to the approved product information.
Is Wegovy 25 mg tablets the starting dose?
No. The published oral schedule starts with lower strengths and progresses through 1.5 mg, 4 mg and 9 mg before reaching 25 mg as the maintenance strength.
How often is Wegovy 25 mg tablets taken?
The oral Wegovy maintenance regimen is once daily. Patients should follow the prescribed instructions and the current Australian product information.
Can I take Wegovy 25 mg tablets with food?
Oral semaglutide has specific fasting and administration requirements. Published instructions recommend taking the tablet after an overnight fast with a small amount of plain water and waiting at least 30 minutes before eating, drinking or taking other oral medicines. Follow the Australian product instructions.
Can I split or crush a Wegovy 25 mg tablet?
Published instructions state that the tablet should be swallowed whole. Do not split, crush or chew it.
Can I switch from Wegovy injections to the 25 mg tablet?
A switch may be possible for some patients, but the formulations have different schedules and administration requirements. A doctor must determine whether a switch is suitable and provide the correct transition plan.
Is Wegovy 25 mg the same as Ozempic?
No. Both products contain semaglutide, but they have different product registrations, approved uses, formulations and dosing schedules. They should not be treated as interchangeable.
Is Wegovy 25 mg available in Australian pharmacies?
The TGA ARTG includes the 25 mg tablet registration. However, registration alone does not confirm current pharmacy stock or a commercial launch date. Check with an Australian pharmacist for current supply information.
Does Wegovy 25 mg require a prescription in Australia?
Wegovy is a prescription medicine. Patients should consult a qualified healthcare professional to determine whether treatment is appropriate.
Medical Disclaimer
This page is intended for general educational purposes only. It does not provide individual medical advice, diagnosis or treatment recommendations. Wegovy is a prescription medicine and should only be used under the supervision of a qualified healthcare professional.
Product registration, approved indications, dosing instructions, safety information and supply status may change. Always consult the latest Australian Product Information and Consumer Medicine Information and speak with a doctor or pharmacist before starting, stopping or changing treatment.
Editorial review note: Before publication, verify all dosage, administration, indication and safety statements against the current Australian PI and CMI for ARTG 522759. Update the page when official product information or supply status changes.
Important regulatory consideration: Prescription-only medicines have strict advertising restrictions in Australia under the Therapeutic Goods Act and TGA advertising requirements. Public-facing promotion of prescription-only Wegovy, including product-specific promotional descriptions, calls to purchase and testimonials, can be problematic. Keep these pages educational and non-promotional, and obtain Australian regulatory review before publishing commercial product listings.
- Wegovy 1.5 mg Tablets
- Wegovy 4 mg Tablets
- Wegovy 9 mg Tablets
- Wegovy Tablets in Australia
- Semaglutide: Uses, Safety and Medical Information
Useful references:
Reviews
There are no reviews yet.